1	"May" May 2002
2	Company Overview NeuroVision has developed non-invasive vision correction technology based on breakthroughs in the field of neuroscience NeuroVision leverages discoveries in adult neural plasticity and in our understanding of the neural connections responsible for vision NeuroVision’s technology is formed around its proprietary algorithms, which are delivered via the Internet to home-based workstations
3	Market Opportunities NeuroVision’s first commercial product will address the worldwide low myopia (<1.5D) market: Europe 35M North America 28M Japan 23M Asia/Pacific 12M
4	Product Description NeuroVision’s PC-based treatment workstation is comprised of the following: High resolution display monitor Distance sensor Ambient light meter Treatment workstations deliver subject-specific stimuli (interactive Visual Perception Tasks) Repetitive performance of VPTs improves the subject’s Contrast Sensitivity Function (CSF) and resolution (VA) by improving the connectivity among cells in the visual cortex
5	Neural Processing of Vision
6	Classical Receptive Fields - CRF
7	Neuronal Excitation & Inhibition
8	Neural Activity Determines CSF
9	Different Target-Flankers Separations
10	Modulation of Contrast Response
11	Brain Plasticity
12	Practicing Contrast Modulation
13	NeuroVision Treatment Neural inefficiencies/deficiencies are identified Patient-specific stimuli is administered in a controlled environment: Spatial Frequencies Contrast Orientation Order Context Timings
14	Examples of Stimuli Flow
15	Amblyopia Treatment - Improvement of CSF
16	Improved BCVA in Amblyopes
17	Improved BCVA in Myopic Amblyopes
18	Stability of Improvement
19	Myopia
20	Improved UCVA in Myopia
21	Treatment Flow
22	Business Model Provides Incremental Operating Profits to Care Providers: $53K @ 120 patients/year $81K @ 180 patients/year $108K @ 240 patients/year
23	Providers Market European Eye Care Providers: 28,800 ophthalmologists, 18,000 non-surgical (Ger, It, Spa, Fra, UK) 10,000 optometrists in the UK 18,000 US Ophthalmology Providers: 2,700 solo practices 1,500 groups, incorporating 11,000 ophthalmologists 1,800 part of multi-specialty clinics 35,000 US optometry doctors: 18,000 clinics 10 major chains control 25% of the market (Pearl Vision, LensCrafters,…)
24	Provider Model
25	The Company Delaware Corporation, founded 12/99 Headquarters in Wellesley, MA Investors: Concord Ventures AG-Tech Fund Shamrock Holdings Board of Directors: Batsheva Elran, Concord Ventures Shai Schiller, Concord Ventures Yoav Millet, AG-Tech Fund Arthur Rosenthal, SVP & CSO, Boston Scientific Uri Polat, PhD, Founder
26	Management Team Bernard Haffey, CEO Former EVP and Chief Commercial Officer of Summit Technology Dov Sella, President EVP Marketing, VP R&D of UltraGuide, Director – program management, Elbit Systems Uri Polat, PhD, Founder and CSO Leading Scientist in the areas of Neurobiology and Brain Research. Trained at the Weizmann Institute of Science, Tel-Aviv University, School of Medicine Nir Ellenbogen, VP R&D - NeuroVision Ltd. 15 years of software development leadership with Elbit Systems, DSI and the IAF
27	Intellectual Property Continuous build of strong proprietary position around: Patient-specific NVC treatment algorithms Method of NVC technology delivery 4 patents filed including US and PCT Ongoing patenting of future products Assisted by IP specialty law firm Lyon&Lyon
28	Summary Pioneer the development of Neural Vision Correction (NVC) technology Proprietary platform technology, based on 2 decades of neuroscience research Multi-Billion dollars markets Excellent clinical results High margin revenue model Strong Proprietary position, first-mover advantage